Melphalan Culprit or Confounder in Acute Encephalopathy during Autologous Hematopoietic Stem Cell Transplantation?
We report a case of a female patient with Durie-Salmon stage 3A/ISS stage I IgG kappa multiple myeloma (MM) who developed encephalopathy after high-dose melphalan and hematopoietic stem cell transplant (HSCT). The most common etiologies for encephalopathy such as infection, narcotic medications, met...
Main Authors: | Diógenes Alayón-Laguer, Melissa Alsina, Jose L. Ochoa-Bayona, Ernesto Ayala |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Case Reports in Transplantation |
Online Access: | http://dx.doi.org/10.1155/2012/942795 |
Similar Items
-
Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia?
by: Roberto M Lemoli, et al.
Published: (2011-06-01) -
Long-term outcomes of innovator versus generic melphalan formulation in autologous hematopoietic cell transplantation for multiple myeloma
by: Deepesh P. Lad, et al.
Published: (2021-06-01) -
Autologous hematopoietic stem cell transplantation for systemic scleroderma
by: R T Alekperov, et al.
Published: (2012-08-01) -
Altered T-Lymphocyte Biology Following High-Dose Melphalan and Autologous Stem Cell Transplantation With Implications for Adoptive T-Cell Therapy
by: Thomas Mika, et al.
Published: (2020-12-01) -
Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission
by: Nadjanara Dorna Bueno, et al.
Published: (2011-06-01)